Skip to main content
. 2022 Feb 28;1(1):e000036. doi: 10.1136/bmjmed-2021-000036

Figure 3.

Figure 3

Risk of bias of trials included in network meta-analysis comparing tocilizumab and sarilumab for covid-19, alone or in combination with corticosteroids, and trials comparing corticosteroids with standard care or interleukin 6 receptor blockers